In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portola Pharmaceuticals Inc.

www.portola.com

Latest From Portola Pharmaceuticals Inc.

Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen

The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.

Financing Strategy

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances now includes two new products, one of which is bluebird bio's genetically modified product for treating beta-thalassemia, Zynteglo. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

Approvals Europe

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances now includes five new products, one of which is BioMarin Pharmaceutical's Palynziq for treating phenylketonuria. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

Approvals Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Portola Pharmaceuticals Inc.
  • Senior Management
  • Scott Garland, Pres. & CEO
    Mardi C Dier, EVP, CFO & CBO
    Sheldon Koenig, Chief Commercial Officer
    Jeff Myers, MD, PhD, Interim CMO & VP, Med. Affairs
  • Contact Info
  • Portola Pharmaceuticals Inc.
    Phone: (650) 246-7000
    270 E. Grand Ave.
    So. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register